FDA Codifies Home-Collected STI Nucleic Acid Testing Under 21 CFR 866.3385: Class II, 510(k) Still Required

FDA Codifies Home-Collected STI Nucleic Acid Testing Under 21 CFR 866.3385

On 9 October 2026, the U.S. Food and Drug Administration published a final amendment and final order in the Federal Register adding a new device generic type under 21 CFR 866.3385: systems that use home-collected specimens to detect nucleic acid from non-viral microorganisms causing sexually transmitted infections. The device type is placed in Class II with special controls. The order states an effective date of 9 October 2026 and, at the same time, states that the classification applies as of 15 November 2023. Read together, the two statements explain the nature of the action: a classification decision originally made through the De Novo pathway in 2023 is now formally codified in the federal regulations.

The classification originates from a De Novo request submitted by LetsGetChecked in 2020 and granted on 15 November 2023. The present order converts the existing classification into regulatory text. Products within this type may be intended for prescription or over-the-counter (OTC) use, and premarket notification (510(k)) is still required; no exemption has been granted. The special controls impose specific requirements on collection devices, evidence for use by lay users, clinical studies by specimen type, transport stability, and labeling.

Source: U.S. Food and Drug Administration — Federal Register final order (21 CFR 866.3385), 9 October 2026. https://www.federalregister.gov/documents/2026/10/09/2026-20727/medical-devices-immunology-and-microbiology-devices-classification-of-the-system-for-detection-of

Article information

• Category: Product Approval and Registration
• Published: 24 October 2026, 13:38

1. Which Products the Regulation Covers

Under 866.3385(a), the device type covers in vitro diagnostic systems intended for self-collection of specimens at home or in a similar environment, with the specimen then sent to a clinical laboratory for testing to detect nucleic acid from non-viral pathogens that cause sexually transmitted infections, in order to aid in the diagnosis of sexually transmitted infections. The intended use may be stated as prescription use or as non-prescription (OTC) use. In other words, the regulation does not govern a single company’s test kit; it governs an entire category of “self-collected specimen plus laboratory nucleic acid testing” combinations.

2. Three Dates to Keep Separate

The timeline should be cited precisely rather than summarized as a “new classification in 2026”:

• 16 November 2020 — FDA received a De Novo classification request from LetsGetChecked Inc. (formerly PrivaPath Diagnostics Inc.) for the Simple 2 Test.
• 15 November 2023 — FDA issued a Class II classification order for that device.
• 9 October 2026 — the classification was written into the regulations by final order, effective the same day.

Keeping these three dates distinct in regulatory dossiers and submissions is more accurate than referring generically to a newly added 2026 classification.

3. Why Class II Applies and Whether 510(k) Is Still Needed

New devices not commercially marketed in the United States before 28 May 1976 are automatically placed in Class III by statute and require premarket approval. The De Novo pathway allows such devices to be reclassified into Class I or Class II, with special controls managing the risks. The order makes a further point explicit: FDA has not determined, under section 510(m), that this device type should be exempt from premarket notification, so a 510(k) submission is still required. For subsequent applicants, a device of this classified type can serve as a predicate, allowing the 510(k) route rather than a new De Novo request.

4. Special Controls, Part 1: Collection Devices and Lay Users

Special control (1) requires that testing use a specimen collection device that has been cleared or approved by FDA, or classified as 510(k)-exempt, and that carries an intended use for over-the-counter in vitro diagnostic molecular testing. Where that condition is not met, the collection device must be included as part of the device in the premarket submission and cleared with it, and performance data must demonstrate that lay users can perform collection correctly without supervision by a healthcare professional.

Related special control (3) limits the intended use to specimen types that are suitable for self-collection by lay users and are supported by performance data.

5. Special Controls, Part 2: Clinical and Analytical Requirements

Special control (4)(iv) requires a prospective clinical study of self-collected specimens for each claimed specimen type. The study population must be consistent with the intended-use population, and the study must compare results against an FDA-recognized comparator method. The documentation must include a study protocol with a pre-specified statistical analysis plan, a study report, and the test results and statistical analysis results.

Special control (4)(v) requires a risk management file that includes usability studies, label comprehension studies, and flex studies.

Special control (4)(vi) lists the analytical studies required: limit of detection, inclusivity, cross-reactivity, microbial interference, interfering substances, competitive inhibition, carryover and cross-contamination, specimen stability, within-laboratory precision, and reproducibility.

Additional requirements include:

• (4)(vii) separate verification of specimen integrity during handling and transport;
• (4)(viii) reagent stability;
• (4)(ix) for devices involving software or instrumentation, a software description together with verification and validation, hazard analysis, and risk assessment.

6. Special Controls, Part 3: Labeling, Instructions for Use and Outer Packaging

Special control (5) requires the instructions for use to clearly describe specimen collection, packaging, shipping, interpretation of results, and follow-up actions, and to include seven warnings:

• a negative result does not rule out infection with other pathogens;
• the test does not replace medical evaluation;
• individuals with a recent history of exposure should seek medical care promptly;
• individuals with impaired vision or limited dexterity should consult a healthcare professional before collecting a specimen;
• result accuracy depends on proper storage and handling;
• improper procedure can produce erroneous results;
• expired kits must not be used.

Special control (5)(ii) also requires a set of FAQs covering partner notification, prevention, what to do if symptoms persist after treatment, and sources of information on the disease.

Special control (6) requires labeling to provide a prominent link to the manufacturer’s public website. The website must disclose the purpose of the test, collection and shipping steps, interpretation of results, warnings and limitations, and technical support contact details. For OTC products, the website must also state who is suitable and who is not suitable for use, provide a pathway to follow-up medical care or telehealth consultation, and publish performance characteristics.

Special control (7) requires the outer packaging to state the intended user population and age, the list of components, components the user must supply, the requirement to return the specimen to the laboratory within the specified timeframe, and a partner-notification notice.

7. A Boundary That Is Easy to Overlook

The order notes that, at the time of classification, systems within this type included products intended for prescription use only. Prescription devices must also comply with the prescription labeling requirements of 21 CFR 809.10. In other words, the fact that a classification permits OTC use does not mean that any product may be marketed as OTC; the applicable pathway depends on each product’s specific intended use and submission data.

Source and Verification

Source: U.S. Food and Drug Administration — Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens (Final amendment; final order, Docket No. FDA-2026-N-10996), Federal Register, issue of 9 October 2026, effective date 9 October 2026. Original text: https://www.federalregister.gov/documents/2026/10/09/2026-20727/medical-devices-immunology-and-microbiology-devices-classification-of-the-system-for-detection-of

Scope of verification and access date: the full text of the order was reviewed, including the regulatory text of 21 CFR 866.3385, special controls (1) through (7), the effective date, and the De Novo request timeline. Access date: 24 October 2026.

Applicability note: this article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company, or registration application. Regulatory text and dates are governed by the official source, and the information may change with subsequent official updates.

AIMEILI Regulatory Interpretation

This final order is best understood as a codification rather than a new regulatory burden. The substantive classification decision was already in force from 15 November 2023 through the De Novo grant for the Simple 2 Test; the 9 October 2026 order gives that decision a permanent place in 21 CFR. For manufacturers already preparing home-collected STI molecular tests, the practical consequence is that the regulatory expectations are now explicit, citable, and stable, which makes gap assessment and dossier planning more predictable.

Three points deserve particular attention in submission strategy:

• Predicate availability. Because the device type is now classified and not exempt, a new entrant can file a 510(k) against a cleared predicate rather than pursuing a De Novo. This generally shortens the pathway, but the applicant must still demonstrate substantial equivalence, including for specimen type, intended-use population, and OTC versus prescription claims.
• Specimen type as the unit of evidence. Special control (4)(iv) requires a prospective self-collection clinical study for each claimed specimen type. A submission that claims multiple specimen types should plan separate studies, each with its own pre-specified statistical analysis plan and comparison against an FDA-recognized comparator method.
• The collection device is a critical dependency. Special control (1) effectively requires either an already-cleared, approved, or 510(k)-exempt collection device labeled for OTC molecular IVD use, or inclusion of the collection device in the applicant’s own submission with lay-user performance data. Suppliers and device configurations should be locked early, because this requirement can determine the scope and timing of the entire 510(k).

The special controls also function as a de facto content checklist for the premarket submission: analytical studies under (4)(vi), specimen integrity during handling and transport under (4)(vii), reagent stability under (4)(viii), and software and instrument documentation under (4)(ix). For lay-user products, the usability, label comprehension, and flex studies required by (4)(v) are frequently the items that drive timelines, and they should be scheduled alongside, not after, the clinical study.

Labeling obligations under (5), (6), and (7) extend beyond the package insert to the manufacturer’s public website, including performance characteristics, suitability statements, and a documented route to follow-up care or telehealth. Global manufacturers should therefore plan website content and its maintenance as part of the regulatory deliverables, not as a marketing task.

Finally, the boundary noted in Section 7 matters commercially. A classification that permits OTC use does not confer OTC status on any particular product; a prescription-only version remains subject to 21 CFR 809.10. Companies should decide early whether the target claim is prescription or OTC, since that choice drives the lay-user evidence package, labeling content, and website disclosures.

Business Impact

For global medical device manufacturers, distributors, CROs, and regulatory affairs teams, the codification has several practical consequences:

• Lower procedural risk for U.S. market entry. A 510(k) pathway with a known predicate and published special controls reduces the uncertainty that previously surrounded novel home-collected STI tests, and makes budget and timeline estimates more defensible for management review.
• Higher front-end evidence costs. Per-specimen-type prospective clinical studies, lay-user usability and label comprehension studies, flex studies, transport integrity validation, and reagent stability testing represent a substantial pre-submission investment. Early gap analysis and, where appropriate, a Pre-Submission (Q-Sub) meeting can reduce the risk of repeat studies.
• Supply chain and partner selection. Collection device status under special control (1) should be confirmed with suppliers before design freeze; a non-compliant collection device can force an expansion of the submission scope and delay clearance.
• OTC versus prescription portfolio decisions. OTC claims open the consumer and retail channel but require the full lay-user evidence set, website disclosures, and suitability statements. A prescription-first strategy may reach the U.S. market faster while an OTC version is developed in parallel.
• Distributor and CRO readiness. U.S. distribution partners will expect documented 510(k) clearance, labeling compliant with (5) through (7), and a maintained public website. CROs and testing laboratories supporting these programs should align protocols with the special-control requirements, particularly the pre-specified statistical analysis plan and the use of FDA-recognized comparator methods.
• Documentation and lifecycle maintenance. Because the requirements are now codified, changes to specimen types, collection devices, software, or labeling claims should be assessed against 21 CFR 866.3385 and reflected in a letter-to-file, new 510(k), or other appropriate submission, with the public website updated in step with the cleared labeling.

Overall, the order signals that home-collected STI nucleic acid testing is an established, regulated U.S. device category. Manufacturers that treat the special controls as a complete design and evidence specification, rather than as a post hoc documentation exercise, will be best positioned to compete in this segment.

Source: U.S. Food and Drug Administration — Federal Register final order (21 CFR 866.3385), 9 October 2026.